Physician profile
Todd J Yates
NPI 1710197447
$9,241.70
in general payments reported to CMS, 2019-2025
53 companies · $2,312 in 2025
The $2,312 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,244 · 2020: $395 · 2021: $111 · 2022: $1,127 · 2023: $1,779 · 2024: $2,274 · 2025: $2,312.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,306 · Education: $59.11.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,305.87 |
| Education | $59.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $683.72 | 2019-2025 | |
| Pfizer INC. | $611.42 | 2019-2025 | |
| Emd Serono, INC. | $483.57 | 2022-2025 | Tepmetko, Bavencio |
| Eisai INC. | $436.32 | 2019-2025 | |
| Celgene Corporation | $429.59 | 2019-2025 | Reblozyl, Opdualag, Pomalyst |
| Astrazeneca Pharmaceuticals LP | $404.76 | 2022-2025 | Imfinzi, Enhertu, Calquence |
| Merck Sharp & Dohme LLC | $396.27 | 2019-2025 | Keytruda, Lynparza, Keytruda Qlex |
| E.R. Squibb & Sons, L.L.C. | $357.54 | 2019-2025 | Opdivo, Opdualag |
| Gilead Sciences, INC. | $352.97 | 2019-2025 | Trodelvy |
| Genentech USA, INC. | $351.03 | 2019-2025 | Tecentriq, Tecentriq Hybreza, Phesgo |
| Array Biopharma INC | $339.70 | 2019-2025 | Lorbrena, Braftovi, Mektovi |
| Abbvie INC. | $330.55 | 2022-2025 | Venclexta |
| Pharmacyclics LLC, An Abbvie Company | $282.03 | 2022-2023 | Imbruvica, Epkinly |
| Adc Therapeutics America, INC. | $271.98 | 2021-2022 | |
| Janssen Biotech, INC. | $270.22 | 2019-2025 | Carvykti, Imbruvica, Tecvayli |
Show all 53 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $260.34 | 2019-2025 | Xtandi, Vyloy |
| Seagen INC. | $241.36 | 2019-2023 | Adcetris, Tukysa |
| Exelixis INC. | $236.07 | 2019-2024 | Cabometyx |
| Daiichi Sankyo INC. | $226.41 | 2020-2025 | Enhertu, Injectafer |
| Alexion Pharmaceuticals, INC. | $226.37 | 2022-2025 | Ultomiris |
| Incyte Corporation | $204.99 | 2023-2025 | Jakafi, Pemazyre, Monjuvi |
| Glaxosmithkline, LLC. | $199.54 | 2020-2025 | Ojjaara, Zejula, Jemperli |
| Amgen INC. | $198.56 | 2019-2023 | Nplate, Xgeva, Vectibix |
| Dendreon Pharmaceuticals LLC | $182.29 | 2019-2025 | Provenge |
| Takeda Pharmaceuticals U.S.A., INC. | $112.57 | 2019-2025 | Ninlaro, Iclusig |
| Kite Pharma, INC. | $101.48 | 2022-2023 | |
| Stemline Therapeutics INC. | $96.66 | 2024-2025 | Orserdu, Elzonris |
| Beigene USA, INC. | $92.05 | 2020 | |
| Blueprint Medicines Corporation | $90.56 | 2020-2021 | |
| Karyopharm Therapeutics INC. | $84.90 | 2025 | Xpovio |
| Pharmaessentia USA Corporation | $78.96 | 2022-2025 | Besremi |
| Genzyme Corporation | $77.00 | 2023-2024 | |
| Sobi, INC | $63.19 | 2024-2025 | |
| Agios Pharmaceuticals, INC. | $44.23 | 2024-2025 | Pyrukynd |
| Alnylam Pharmaceuticals INC. | $40.00 | 2024-2025 | Amvuttra, Onpattro |
| Teva Pharmaceuticals USA, INC. | $38.61 | 2020 | |
| Mirati Therapeutics, INC. | $36.34 | 2023-2024 | Krazati |
| Caris Mpi, INC. | $29.66 | 2025 | Mi Cancer Seek |
| Recordati_rare_diseases_inc. | $29.38 | 2025 | Sylvant |
| Verity Pharmaceuticals INC. | $24.39 | 2024 | Trelstar |
| Puma Biotechnology, INC. | $24.08 | 2025 | |
| Myriad Genetic Laboratories, INC. | $23.44 | 2024 | Myrisk |
| Sun Pharmaceutical Industries INC. | $23.31 | 2020 | |
| Coherus Oncology, INC. | $23.05 | 2025 | Loqtorzi |
| Servier Pharmaceuticals LLC | $22.69 | 2023 | |
| Deciphera Pharmaceuticals INC. | $22.48 | 2025 | Qinlock, Romvimza |
| Ge Healthcare | $18.81 | 2022 | |
| Accord Healthcare, INC. | $14.37 | 2024 | |
| Foundation Medicine, INC. | $13.96 | 2019 | |
| Janssen Pharmaceuticals, INC | $12.96 | 2023 | |
| Tolmar Pharmaceuticals, INC. | $12.50 | 2022 | |
| Tesaro, INC. | $11.96 | 2019 | |
| Clovis Oncology, INC. | $0.51 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Todd Yates listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.